文献速递衰弱、肌少症与跌倒多重用药老年慢病共病管理

他汀类药物用于老年人一级预防:迈向循证决策

Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making.
PubMed 文献 · J Am Geriatr Soc · 2018-10-02

美国国家老龄化研究所与心肺血液研究所召集多学科专家小组,综述现有证据并识别知识缺口。结论认为现有数据无法回答75岁及以上无ASCVD老年人(尤其合并多病、衰弱和认知障碍者)使用他汀一级预防的获益与风险,需开展随机对照试验。

要点

  • 现有证据不足以明确75岁及以上老年人他汀一级预防的获益与风险。
  • 衰弱、多重用药、共病和认知障碍人群的他汀数据尤其缺乏。
  • 缺乏80岁及以上人群的ASCVD风险评估工具。

核心结论

  • 现有数据无法解决75岁及以上成人他汀一级预防ASCVD的获益与风险不确定性,尤其合并多病、衰弱和认知障碍者。
  • 需要一项或多项随机对照试验证据来填补知识缺口,支持以人为中心的决策。

研究设计与样本

  • 美国国家老龄化研究所和国家心肺血液研究所于2017年7月31日至8月1日召集多学科专家小组召开研讨会。
  • 研讨会审查现有证据、识别知识缺口,并讨论未来他汀试验的可行性、设计和实施。
  • 本文总结该研讨会的报告和讨论内容。

主要发现

  • 关于他汀在老年人中的获益和危害证据不足,尤其合并衰弱、多重用药、共病和认知障碍者。
  • 缺乏评估80岁及以上人群ASCVD风险的工具。
  • 缺乏他汀对老年人重要结局(如他汀相关肌肉症状、认知功能和 incident 糖尿病)影响的证据。
  • 现有大型医疗网络的可行性分析确认,未来随机对照试验在死亡和心血管结局方面有适当把握度。

关键数值与推荐

  • 现有证据不足以评估他汀在75岁及以上无ASCVD老年人中的获益和危害。
  • 前瞻性、传统、安慰剂对照随机临床试验和实用性随机临床试验似乎是解决关键知识缺口的合适选择。
  • 未来试验须考虑高龄老人、女性、代表性不足的少数群体以及不同健康、认知、社会经济和教育背景个体的更大代表性。

临床怎么用

  • 对75岁及以上无ASCVD老年人启动他汀一级预防时,应认识到获益与风险证据不足。
  • 决策时应考虑衰弱、多重用药、共病和认知障碍等个体因素,并关注他汀相关肌肉症状、认知功能和 incident 糖尿病。
  • 应与患者进行以人为中心的决策讨论,说明证据不确定性。

局限性

  • 本文为研讨会总结,非系统综述或原始研究。
  • 现有证据不足以回答75岁及以上人群他汀一级预防的关键问题。
  • 缺乏80岁及以上人群的ASCVD风险评估工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the efficacy and safety of statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) events in older adults, especially those aged 80 and older and with multimorbidity. METHODS: The National Institute on Aging and the National Heart, Lung and Blood Institute convened A multidisciplinary expert panel from July 31 to August 1, 2017, to review existing evidence, identify knowledge gaps, and consider whether statin safety and efficacy data in persons aged 75 and older without ASCVD are sufficient; whether existing data can inform the feasibility, design, and implementation of future statin trials in older adults; and clinical trial options and designs to address knowledge gaps. This article summarizes the presentations and discussions at that workshop. RESULTS: There is insufficient evidence regarding the benefits and harms of statins in older adults, especially those with concomitant frailty, polypharmacy, comorbidities, and cognitive impairment; a lack of tools to assess ASCVD risk in those aged 80 and older; and a paucity of evidence of the effect of statins on outcomes of importance to older adults, such as statin-associated muscle symptoms, cognitive function, and incident diabetes mellitus. Prospective, traditional, placebo-controlled, randomized clinical trials (RCTs) and pragmatic RCTs seem to be suitable options to address these critical knowledge gaps. Future trials have to consider greater representation of very old adults, women, underrepresented minorities, and individuals of differing health, cognitive, socioeconomic, and educational backgrounds. Feasibility analyses from existing large healthcare networks confirm appropriate power for death and cardiovascular outcomes for future RCTs in this area. CONCLUSION: Existing data cannot address uncertainties about the benefits and harms of statins for primary ASCVD prevention in adults aged 75 and older, especially those with comorbidities, frailty, and cognitive impairment. Evidence from 1 or more RCTs could address these important knowledge gaps to inform person-centered decision-making. J Am Geriatr Soc 66:2188-2196, 2018.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Singh S, Zieman S, Go AS, et al. Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making. J Am Geriatr Soc. 2018. PMID: 30277567. doi:10.1111/jgs.15449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。